

LONDON
SCHOOL of
HYGIENE
& TROPICAL
MEDICINE



Dorsey, G; Dokomajilar, C; Kiggundu, M; Staedke, SG; Kanya, MR; Rosenthal, PJ (2004) Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. *The American journal of tropical medicine and hygiene*, 71 (6). pp. 758-63. ISSN 0002-9637

Downloaded from: <http://researchonline.lshtm.ac.uk/10209/>

DOI:

Usage Guidelines

Please refer to usage guidelines at <http://researchonline.lshtm.ac.uk/policies.html> or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Copyright the publishers

PRINCIPAL ROLE OF DIHYDROPTEROATE SYNTHASE MUTATIONS IN MEDIATING RESISTANCE TO SULFADOXINE-PYRIMETHAMINE IN SINGLE-DRUG AND COMBINATION THERAPY OF UNCOMPLICATED MALARIA IN UGANDA

GRANT DORSEY, CHRISTIAN DOKOMAJILAR, MOSES KIGGUNDU, SARAH G. STAEDKE, MOSES R. KAMYA, AND PHILIP J. ROSENTHAL

Department of Medicine, San Francisco General Hospital, University of California, San Francisco, California; Makerere University Medical School, Kampala, Uganda

Abstract. Antimalarial resistance to sulfadoxine-pyrimethamine (SP) is mediated by mutations in the dihydrofolate reductase (*dhfr*) and dihydropteroate synthase (*dhps*) genes. However, the relative importance of different mutations is incompletely understood and has not been studied with combination therapy. Samples from 812 patients treated for uncomplicated malaria in Kampala, Uganda were tested for the presence of mutations commonly found in Africa. The *dhps* Glu-540 mutation was the strongest independent predictor of treatment failure. The *dhfr* Arg-59 mutation was only predictive of treatment failure in the presence of the *dhps* Glu-540 mutation. Comparing combination regimens with SP monotherapy, the addition of chloroquine to SP did not improve efficacy, the addition of artesunate lowered the risk of treatment failure only for infections with both the *dhfr* Arg-59 and *dhps* Glu-540 mutations, and the addition of amodiaquine lowered this risk for all *dhfr/dhps* mutation patterns. The *dhps* Glu-540 mutation played a principal role and the *dhfr* Arg-59 mutation a secondary role in mediating resistance to SP alone and in combination.

INTRODUCTION

Sulfadoxine-pyrimethamine (SP) is currently the first-line antimalarial therapy in several African countries where chloroquine (CQ) resistance is widespread and other drugs remain too expensive for general use.¹ It is generally regarded as a single antimalarial agent because its success depends on the synergistic action of its two component inhibitors of folate synthesis.² Resistance to SP spread rapidly in southeast Asia following widespread use³ and is now spreading in Africa.⁴ In an attempt to improve treatment efficacy and delay the spread of drug resistance, several countries in Africa recently changed to inexpensive combinations of SP plus CQ or amodiaquine (AQ) as first-line antimalarial therapy.¹ In addition, many authorities advocate combinations with artesunate (AS) or other artemisinins, including SP plus AS,⁵ although these regimens are expensive.

Resistance to SP is caused by point mutations that accumulate at several sites in the dihydrofolate reductase (*dhfr*) and dihydropteroate synthase (*dhps*) genes, resulting in increasing degrees of drug resistance *in vitro*.^{2,6} For *dhfr*, a point mutation at position 108 (Ser→Asn) increases resistance to pyrimethamine approximately 100-fold.⁷ The addition of mutations at positions 51 (Asn→Ile) and 59 (Cys→Arg) progressively enhances *in vitro* resistance to pyrimethamine.² The relationship between *dhps* mutations and *in vitro* resistance to sulfadoxine is less clear, in part because the *in vitro* measurement of sulfadoxine activity is complex due to differences in assay conditions and variations in the ability of different parasite strains to use exogenous folate.^{2,6,8} Nevertheless, it appears that *in vitro* resistance to sulfadoxine is associated with accumulation of point mutations in the *dhps* gene.⁹

Assessment of molecular markers of SP resistance has been proposed as a means of monitoring *in vivo* drug resistance. However, many questions remain about the relationship between *dhfr* and *dhps* mutations that confer *in vitro* resistance and clinical treatment outcomes. The *dhfr* Asn-108 mutation alone does not appear to be sufficient to confer clinical drug resistance.¹⁰ The *dhfr* triple mutant (Asn-108 + Ile-51 + Arg-

59) has been suggested as a useful predictor of treatment failure by some investigators,^{11,12} although others have not found useful predictive value for this genotype.^{13,14} Others have suggested that the most useful predictor of SP treatment failure is a combination of the *dhfr* triple mutant and two *dhps* mutations (Gly-437 + Glu-540).^{15,16} A better understanding of the relationship of key *dhfr* and *dhps* mutations in field isolates and of the independent roles of each mutation in mediating response to therapy will be helpful in directing the rational use of SP and SP-containing combination regimens.

In this study, we evaluated the relationship between key *dhfr* and *dhps* mutations in a large sample of patients (n = 812) with uncomplicated *Plasmodium falciparum* malaria from three clinical trials conducted over a five-year period in Kampala, Uganda. In addition, we evaluated combinations of *dhfr* and *dhps* alleles to identify the strongest predictors of treatment failure, and we compared the relationship between allelic risk groups and response to SP monotherapy and three SP combination therapies (SP + CQ, SP + AQ, and SP + AS).

MATERIALS AND METHODS

Study site and subjects. All studies were conducted between March 1999 and June 2003 at the outpatient department of Mulago Hospital in Kampala, the urban capital of Uganda. Malaria is mesoendemic in Kampala, with peak transmission occurring during two rainy seasons (Ugandan Ministry of Health, unpublished data). Patients included in this analysis came from three previously published clinical trials. The treatment arms and study dates are as follows: study 1; CQ versus SP, March 1999 to August 1999¹⁷; study 2; SP versus SP + AQ versus SP + AS, July 2000 to August 2001¹⁸; and study 3; SP + CQ versus SP + AQ versus AQ + AS, August 2002 to July 2003 (Staedke SG, unpublished data). Only patients enrolled in SP monotherapy arms or SP combination therapy arms (SP + CQ, SP + AQ, or SP + AS) fulfilling the following selection criteria were included in this study: 1) age range = 6 months to 10 years, 2) tympanic temperature $\geq 38^{\circ}\text{C}$ or a history of fever in the previous 48

hours, 3) absence of severe malaria¹⁹ or danger signs (inability to stand or drink, lethargy, recent convulsions, persistent vomiting), 4) willingness to provide informed consent, 5) residence within Kampala 6) *P. falciparum* mono-infection, 7) parasite density ≥ 500 asexual parasites/ μL , and 8) successful outcome classification after 28 days of follow-up, adjusted for genotyping.

Informed consent was obtained from all adult participants and from parents or legal guardians of minors. All protocols were reviewed and approved by the Institutional Review Boards of Makerere University, Kampala and the University of California, San Francisco.

Patient follow-up and outcome classification. Standardized clinical outcomes for all subjects were assessed using the 1996 World Health Organization (WHO) clinical classification system (adequate clinical response [ACR], early treatment failure [ETF], or late treatment failure [LTF])²⁰ with follow-up extended to 28 days and the modification that after day 3, patients with parasitemia and a history of recent fever (not documented) were considered LTF. For subjects with recurrent parasitemia after day 4, pretreatment samples and samples from the day of treatment failure were analyzed for polymorphisms in merozoite surface protein 2 to distinguish recrudescence from new infections, according to previously published methods.²¹ Genotyping was successful in 97% of the samples analyzed. For the purposes of this study, treatment failure was defined as fulfillment of the WHO criteria for ETF or LTF in the presence of recrudescence parasites.

Mutation analysis. The presence of *dhfr* Asn-108, Ile-51, and Arg-59 and *dhps* Gly-437 and Glu-540 mutations commonly found in Africa were determined using a nested polymerase chain reaction amplification followed by restriction enzyme digestion. All five mutations were assessed in the SP monotherapy group and only the *dhfr* Arg-59 and *dhps* Gly-437 and Glu-540 mutations were assessed in the combination therapy groups. Blood was collected on filter paper on the day of diagnosis and parasite DNA isolated using the Chelex extraction method.²² Primers, amplification conditions, and restriction endonucleases for assays to detect all mutations were as previously described.^{15,23} Digestion products were visualized by gel electrophoresis and results were classified as wild-type, pure mutant, or mixed (both wild-type and mutant alleles present in the same infection) based on the migration patterns of the fragments. Investigators were blinded to clinical outcomes at the time of molecular analysis.

Statistical analysis. Associations between categorical variables were assessed using the chi-square or Fisher's exact test as appropriate. Associations between combinations of *dhfr* and *dhps* mutations and treatment failure were assessed using multivariate logistic regression, controlling for age and parasite density, with treatment and allelic risk groups included as interaction terms. All interaction terms with *P* values ≤ 0.2 were retained in the final model. Graphic presentation of the change in the prevalence of mutations over calendar time was generated using the lowess locally weighted regression smoothing technique. Parasite density was normalized using natural log transformation. All data were entered and verified using Epi-Info version 6.04 (Centers for Disease Control and Prevention, Atlanta, GA) and SPSS (SPSS Inc., Chicago, IL). Analysis was performed using STATA statistical software (Stata Corp., College Station, TX). All confidence levels were set at 95%. Data on the association between molecular markers of SP resistance and clinical outcomes in the SP monotherapy group have been published previously,^{15,24} but were included in this study to improve statistical power and provide a comparison group for the SP-combination therapies.

RESULTS

Patient characteristics and treatment outcomes. A total of 812 subjects from 4 different treatment groups enrolled between March 1999 and April 2003 were included in this study. Compared with the SP monotherapy group (32%), the risk of treatment failure at 28 days was similar in the SP + CQ group (35%; *P* = 0.58) and significantly lower in the SP + AS (17%; *P* = 0.0003) and SP + AQ (7%; *P* < 0.0001) groups (Table 1).

Prevalence and relationship of *dhfr* and *dhps* mutations. We were interested in the prevalence of key *dhfr* (Asn-108, Ile-51, and Arg-59) and *dhps* mutations (Gly-437 and Glu-540) and the relationship between these mutations. A total of 2,832 (97%) of 2,930 molecular assays were successfully performed for *dhfr* Asn-108 and Ile-51 mutations in the SP monotherapy group and for *dhfr* Arg-59 and *dhps* Gly-437 and Glu-540 mutations in all treatment groups. The *dhfr* Asn-108 and Ile-51 mutations were very common, with 88% and 91% of samples having the pure mutant and 97% and 94% having a mixed or pure mutant, respectively (Figure 1). The *dhfr* Arg-59 mutation occurred less commonly and was strongly linked to the *dhfr* Asn-108 and Ile-51 mutations. Of the 161 samples that were mixed or pure mutant for *dhfr* Arg-59, only 3 (2%) were wild-type for *dhfr* Asn-108, 6 (4%)

TABLE 1
Baseline characteristics and treatment outcomes

	Treatment group*			
	SP	SP + CQ	SP + AS	SP + AQ
Number of subjects	247	125	173	267
Studies (n) and enrollment period†	Study 1 (63) Study 2 (184)	Study 3 (125)	Study 2 (173)	Study 2 (138) Study 3 (129)
Median age in years (range)	3.1 (0.5–10)	4.3 (0.5–10)	3.1 (0.6–5.7)	3.1 (0.5–10)
Geometric mean parasite density (per μL)	35,027	24,191	52,727	36,446
Early treatment failure‡ (%)	25 (10%)	2 (2%)	0	5 (2%)
Late treatment failures§ (%)	55 (22%)	42 (34%)	29 (17%)	14 (5%)

* SP = sulfadoxine/pyrimethamine; CQ = chloroquine; AS = artesunate; AQ = amodiaquine.

† Study 1 March 1999–August 1999; Study 2 July 2000–August 2001; Study 3 August 2002–April 2003.

‡ Treatment failure on days 1–3.

§ Treatment failure on days 4–28 adjusted by genotyping.




FIGURE 1. Prevalence of key dihydrofolate reductase (*dhfr*) and dihydropteroate synthetase (*dhps*) mutations for all treatment groups combined.

were wild-type for *dhfr* Ile-51, and none were wild-type for both. The prevalences of the *dhps* Gly-437 and Glu-540 mutations were 61% and 62% for the pure mutant and 80% and 81% for the mixed or pure mutant, respectively (Figure 1). The *dhps* Gly-437 and Glu-540 alleles were strongly linked, with 641 (82%) of 778 samples having the same result and only 56 (7%) of 778 samples wild-type for one *dhps* allele and mixed or pure mutant for the other. Considering relationships between mutations in different genes, there was a significant association between the *dhfr* Arg-59 and *dhps* Glu-540 mutations ($P < 0.001$). However, 94 (12%) of 782 samples contained the *dhfr* Arg-59 mutation in the absence of the *dhps* Glu-540 mutation and 181 (23%) of 782 samples contained the *dhps* Glu-540 in the absence of the *dhfr* Arg-59 mutation. Thus, it was not uncommon for the *dhps* Glu-540 mutation to occur in the absence of the *dhfr* Arg-59 mutation.

Association between *dhfr* and *dhps* alleles and treatment outcomes. To maximize our sample size, we pooled the treatment groups from our three clinical studies and evaluated the association between *dhfr* and *dhps* alleles and response to therapy. To simplify our analysis, we focused only on those alleles that were independent predictors of treatment outcome. Given the very high prevalence of the *dhfr* Asn-108 and Ile-51 mutations and their almost ubiquitous presence in the setting of the *dhfr* Arg-59 mutation, results at the *dhfr* 108 and 51 alleles did not add to the predictive value of the *dhfr* 59 allele alone and were thus not assessed for combination therapy groups. Given the strong association between the *dhps* 437 and 540 alleles, we evaluated their individual predictive values. Considering samples that were *dhps* Gly-437 mixed or pure mutant and *dhps* 540 wild-type, only 1 (4%) of 23 resulted in treatment failure. In contrast, considering samples that were *dhps* Glu-540 mixed or pure mutant and *dhps* 437 wild-type, 8 (24%) of 33 resulted in treatment failure. Based on these findings, we concluded that results for the *dhps* 437 allele did not add to the predictive value of the *dhps* 540 allele alone.

Since *dhfr* 108 and 51 alleles and the *dhps* 437 allele were not independent predictors, further analyses concentrated on the association between *dhfr* 59 and *dhps* 540 alleles and treatment outcomes. Our goal was to identify patterns that best predicted treatment outcomes based on all possible combinations of these two alleles. In this and all subsequent analyses, ETFs were excluded because we previously showed that molecular markers of SP resistance were not associated with ETFs¹⁵; others have suggested that many ETFs are due to slow clearance of parasites without true parasite resistance.¹⁶

Risk of treatment failure was assessed based on *dhfr* 59 and *dhps* 540 alleles. For samples containing the *dhps* 540 wild-type allele (termed the low-risk allelic group), the risk of treatment failure was low (6 of 143, 4%), and this risk was not significantly different across strata based on *dhfr* 59 alleles ($P = 0.38$) (Table 2). For samples containing the *dhps* Glu-540 mixed or pure mutant allele, but excluding *dhfr* Arg-59 + *dhps* Glu-540 pure mutants (termed the intermediate-risk allelic group), the risk of treatment failure was significantly higher (58 of 327, 18%) compared with the low-risk group ($P = 0.0001$). Again, there was no significant difference in the risk of treatment failure for this group across strata based on *dhfr* 59 alleles ($P = 0.80$) (Table 2). For samples containing both the *dhfr* Arg-59 and *dhps* Glu-540 pure mutants (termed the high-risk allelic group), the risk of treatment failure was significantly higher (76 of 283, 27%) compared with the low risk ($P < 0.0001$) and the intermediate risk allelic groups ($P = 0.007$). Thus, the presence of the *dhfr* Arg-59 mutation had an independent effect on the risk of treatment failure only in the presence of the *dhps* Glu-540 pure mutant. In contrast, the presence of the *dhps* Glu-540 mutation had an independent effect on the risk of treatment failure even in the absence of the *dhfr* Arg-59 mutation.

Interestingly, the prevalence of the *dhfr* Arg-59 and *dhps* Glu-540 pure mutants increased over the four-year period during which samples were collected (Figure 2). The average prevalence of the *dhfr* Arg-59 pure mutant increased from 40% in 1999 to 60% in 2003 and the average prevalence of the *dhps* Glu-540 pure mutant increased from 40% in 1999 to 70% in 2003.

Association between *dhfr* and *dhps* alleles and treatment outcomes stratified by treatment group. For SP monotherapy, the risk of treatment failure was 7% for the low-risk allelic group, 23% for the intermediate-risk group, and 37% for the high-risk group (Figure 3). When age and pretreatment parasite density were controlled, differences in these associations were statistically significant (intermediate- versus low-risk allelic groups, odds ratio [OR] = 6.3, $P < 0.001$; high- versus low-risk allelic groups, OR = 14.4, $P < 0.001$) (Table 3). Compared with SP monotherapy, SP + CQ combination therapy was associated with a similar relationship between the *dhfr* 59 and *dhps* 540 allelic risk groups and the risk of treatment failure (Figure 3 and Table 3). Combining AS with

TABLE 2
Association between *dhfr* 59 and *dhps* 540 alleles and late treatment failure*

<i>dhfr</i> 59 Allele	<i>dhps</i> 540 Allele	N	Risk of late treatment failure†	Assigned risk group‡
Wild	Wild	52	2%	Low-risk group‡
Mixed	Wild	22	9%	
Mutant	Wild	69	4%	
Wild	Mixed	41	20%	Intermediate-risk group§
Mixed	Mixed	61	21%	
Mutant	Mixed	43	19%	
Wild	Mutant	135	16%	High-risk group¶
Mixed	Mutant	47	17%	
Mutant	Mutant	283	27%	

* *dhfr* = dihydrofolate reductase; *dhps* = dihydropteroate synthase.

† Treatment failure on days 4–28 adjusted by genotyping.

‡ Low-risk group = *dhfr* 59 any genotype and *dhps* 540 wild-type.

§ Intermediate-risk group = *dhps* Glu-540 mixed or pure mutant (excluding high-risk group).

¶ High-risk group = *dhfr* Arg-59 pure mutant and *dhps* Glu-540 pure mutant.




FIGURE 2. Change in average prevalence of dihydrofolate reductase (*dhfr*) Arg-59 and dihydropteroate synthetase (*dhps*) Glu-540 pure mutants over the duration of the three clinical trials using the lowest locally weighted regression smoothing technique. Study 1 (sulfadoxine-pyrimethamine [SP] monotherapy), March 1999 to August 1999; study 2 (SP monotherapy, SP plus amodiaquine [AQ] and SP + artesunate [AS]), July 2000 to August 2001; study 3 (SP plus CQ and SP plus AQ), August 2002 to July 2003.

SP resulted in an overall reduction in the risk of treatment failure (Figure 3), and the association between *dhfr* Arg-59 and *dhps* Glu-540 mutations and treatment failure remained statistically significant (Table 3). However, samples from the intermediate and high-risk groups had similar risks of treatment failure (OR = 6.3, $P < 0.001$ and OR = 5.3, $P = 0.002$, respectively). Combining AQ with SP also resulted in an overall reduction in the risk of treatment failure (Figure 3); however, compared with samples from the low-risk allelic group, only samples from the high-risk allelic group were associated with treatment failure (OR = 2.8, $P = 0.06$) (Table 3). The associations between *dhfr* and *dhps* allelic risk groups and treatment outcomes presented in Table 3 were not significantly different across different age groups (i.e., there was no evidence of effect modification by age).




FIGURE 3. Treatment failure defined as a late treatment failure on days 4–28 adjusted by genotyping. SP = sulfadoxine-pyrimethamine, CQ = chloroquine, AQ = amodiaquine, AS = artesunate. Low-risk group = dihydrofolate reductase (*dhfr*) 59 any genotype and dihydropteroate synthetase (*dhps*) 540 wild-type; intermediate-risk group = *dhps* Glu-540 mixed or pure mutant (excluding high-risk group); high-risk group = *dhfr* Arg-59 pure mutant and *dhps* Glu-540 pure mutant.

TABLE 3

Association between *dhfr* 59 and *dhps* 540 alleles and late treatment failure for each treatment group*

<i>dhfr/dhps</i> Allelic group	Treatment group	OR (95% CI)†	<i>P</i>
Low-risk group‡	All	1.0 (reference)	–
Intermediate-risk group§	SP	6.3 (2.6–15.5)	< 0.001
	SP + CQ	13.0 (4.7–35.7)	< 0.001
	SP + AS	6.3 (2.6–15.5)	< 0.001
	SP + AQ	0.63 (0.2–2.6)	0.53
High risk-group¶	SP	14.4 (5.6–36.7)	< 0.001
	SP + CQ	23.8 (8.7–65.5)	< 0.001
	SP + AS	5.3 (1.8–15.3)	0.002
	SP + AQ	2.8 (1.0–8.0)	0.06

* *dhfr* = dihydrofolate reductase; *dhps* = dihydropteroate synthase; SP = sulfadoxine/pyrimethamine; CQ = chloroquine; AS = artesunate; AQ = amodiaquine.

† Multivariate logistic regression controlling for age and pretreatment parasite density including significant interaction terms based on treatment and allelic risk groups OR = odds ratio; CI = confidence interval.

‡ Low-risk group = *dhfr* 59 any genotype and *dhps* 540 wild-type.

§ Intermediate-risk group = *dhps* Glu-540 mixed or pure mutant (excluding high-risk group).

¶ High-risk group = *dhfr* Arg-59 pure mutant and *dhps* Glu-540 pure mutant.

DISCUSSION

In this study, we investigated the relationship between key *dhfr* and *dhps* mutations found in Africa and clinical response to SP therapy alone and in combination with other drugs. We developed a simplified predictive model of treatment response based only on the presence of the *dhfr* Arg-59 and *dhps* Glu-540 mutations, largely due to the fact that the presence of these mutations was highly predictive of the *dhfr* triple mutant (Asn-108 + Ile-51 + Arg-59) and the *dhps* double mutant (Gly-437 + Glu-540), respectively. Considering all treatment groups combined, the presence of the *dhps* Glu-540 mutation was a much stronger predictor of clinical treatment failure than the *dhfr* Arg-59 mutation. Indeed, the *dhfr* Arg-59 mutation was only an independent predictor of treatment failure in the presence of the *dhps* Glu-540 pure mutant. Compared with SP monotherapy, the addition of CQ to SP did not improve the risk of treatment failure after controlling for the prevalence of the *dhfr/dhps* allelic risk groups. The addition of AS to SP only lowered the risk of treatment failure due to parasites containing both the *dhfr* Arg-59 and *dhps* Glu-540 pure mutants. The addition of AQ to SP lowered the risk of treatment failure for all *dhfr/dhps* allelic risk groups, and for this combination therapy treatment failure was only associated with the *dhfr* Arg-59 + *dhps* Glu-540 pure mutant.

Several studies from Africa have examined the relationship between key *dhfr* and *dhps* mutations in field isolates. With respect to *dhfr* mutations, it has been proposed that the selection of mutations occurs in a stepwise fashion, first with the selection of the Asn-108 mutation, followed by the selection of mutations Ile-51 and/or Arg-59.²⁵ Data on the selection of *dhps* mutations is less clear. Some studies have reported the presence of the *dhps* Gly-437 mutation in the absence of the Glu-540 mutation^{12,26} or the presence of the Glu-540 mutation only in combination with the Gly-437 mutation,²⁷ suggesting that the Gly-437 mutation is selected first.²⁵ However, the presence of the *dhps* Glu-540 mutation in the absence of the Gly-437 mutation has been reported, although it appears to be uncommon,¹⁶ as was the case in our study. It has been further suggested that common *dhfr* and *dhps* mutations have arisen independently on numerous occasions, with the incremental selection of increasingly resistant parasites over

time.²⁸ However, recent data from South Africa and Tanzania demonstrated that gene flow, rather than the spontaneous generation of new mutations, has been the most common originator of SP resistance.⁴ In that study, a period of rapid deterioration of SP efficacy was linked to a high background prevalence of a single *dhfr* triple mutant allele (Asn-108 + Ile-51 + Arg-59), followed by the spread of a single *dhps* double mutant allele (Gly-437 + Glu-540), each derived from independent ancestral lineages. The findings from our study of strong linkage between the three *dhfr* mutations and, independently, between the two *dhps* mutations, which were substantially increasing in prevalence over the four-year span of our studies in Uganda, are consistent with this more recent understanding of the basis of spread of SP resistance.

The relative importance of *dhfr* versus *dhps* mutations in mediating treatment failure to SP has not been clearly resolved. In Cameroon, the *dhfr* triple mutant was associated with 7 (100%) of 7 treatment failures, but was also present in 26 (44%) of 59 treatment successes.¹² In Gabon, the *dhfr* triple mutant was associated with 9 (82%) of 11 treatment failures, but was also present in 51 (72%) of 71 treatment successes.¹⁴ In both of these studies, there was no clear association between *dhps* mutations and treatment failure, but importantly the *dhps* Glu-540 mutation was not detected at either site and despite the high prevalence of the *dhfr* triple mutant (50–73%), the 28-day risk of SP treatment failure was less than 15%. In studies from east Africa, where the reported risk of SP treatment failure is higher than in west Africa, infection with parasites containing both the *dhfr* triple mutant (Asn-108 + Ile-51 + Arg-59) and the *dhps* double mutant (Gly-437 + Glu-540) was associated with the highest risk of treatment failure.^{16,27} However, due to relatively small samples sizes ($n < 100$) and the highly concordant nature of *dhfr* and *dhps* mutations in field isolates, previous studies have had limited power to evaluate independent associations between these mutations and treatment response. In our study, which benefited from a much larger sample size, we found that the *dhps* Glu-540 mutation (a surrogate marker of the Gly-437 + Glu-540 double mutant) was a strong predictor of treatment failure independent of the *dhfr* Arg-59 mutation (a surrogate marker of the Asn-108 + Ile-51 + Arg-59 triple mutant). In addition, it was not uncommon (23% of the samples) for the *dhps* Glu-540 mutation to occur in the absence of the *dhfr* Arg-59 mutation, contradicting previous suggestions that key *dhps* mutations are rare in the absence of the *dhfr* triple mutant.² In contrast, the *dhfr* Arg-59 mutation was associated with treatment failure only in the presence of the *dhps* Glu-540 mutation. These results are consistent with recent findings from South Africa, where five years after the establishment of the *dhfr* triple mutant, an increase in the risk of SP treatment failure from 20% to 70% coincided with the emergence of the *dhps* double mutant.⁴

A recent detailed report summarized all known Ugandan drug efficacy studies from 1988 to 2000, many of which were previously unpublished, including studies with varied methodologies.²⁹ Between 1988 and 1995, reported rates of parasitologic (RI-RIII) resistance in children up to 15 years of age were 2–58% for CQ and 0–4% for SP. Between 1996 and 2000, rates of parasitologic resistance in children less than five years of age were 36–96% for CQ and 6–33% for SP. In addition, these more recent studies reported rates of clinical treatment failure of 10–81% for CQ and 3–25% for SP. In

2001, the Ugandan Ministry of Health replaced CQ with CQ + SP as first-line therapy for uncomplicated malaria.

Clinical response to antimalarial therapy involves a complex interaction between the parasite, drug, and host immune response. In this study, by restricting our analysis to children recruited from the same target population and controlling for age and parasite density, we were able to minimize the contribution of differences in the host immune response. This allowed us to directly compare associations between molecular markers of SP resistance and clinical response to therapy. The use of SP combination therapy reduced the risk of ETF compared with SP monotherapy (10% versus 1%; $P < 0.001$), probably due to more rapid initial parasite clearance. Surprisingly, the addition of CQ to SP did not lower the risk of LTF compared with SP alone even after controlling for the prevalence of key *dhfr* and *dhps* mutations. Overall, the addition of CQ to SP had no impact on efficacy, and CQ is clearly a poor companion drug for SP where resistance to both drugs is high.^{18,30} Of note, in a previous study from Kampala, the prevalence of the *pfert* Thr-76 mutation (which has been linked to CQ resistance) was 100%, suggesting the ubiquitous nature of resistance to this drug in our patient population.³¹ The addition of AS to SP reduced the risk of LTF, but only in infections with the most resistant parasites (*dhfr* Arg-59 + *dhps* Glu-540 pure mutants). The addition of AQ to SP lowered the risk of LTF for all *dhfr/dhps* allelic risk groups, and LTF was only associated with the *dhfr* Arg-59 + *dhps* Glu-540 pure mutant. In our patient population, the combination of SP + AQ was the most effective regimen, but also resulted in the strongest selective pressure for parasites most resistant to SP because almost all treatment failures carried the *dhfr* Arg-59 + *dhps* Glu-540 pure mutant. Thus, concern remains about the useful therapeutic lifespan of SP + AQ in areas where pre-existing resistance to SP is high.

In summary, field studies of molecular markers of SP resistance can be useful for improving our understanding of the determinants of the clinical response to therapy. A combination of the *dhfr* Arg-59 mutation (a surrogate marker of the *dhfr* triple mutant) and the *dhps* Glu-540 mutation (a surrogate marker of the *dhps* double mutant) is the strongest predictor of treatment failure in Africa. Contrary to some prior suggestions, in our study the *dhps* Glu-540 mutation played a greater role in response to therapy than that of the *dhfr* Arg-59 mutation. Since more expensive antimalarial regimens, such as artemisinin-based combination therapy, remain beyond the reach of most African countries, SP combination therapies have been adopted as first-line treatment in a number of African countries. A better understanding of the relationship between molecular markers of SP resistance and response to therapy should help in establishing rational combination therapy policies and in estimating the useful therapeutic life span of these regimens.

Received May 5, 2004. Accepted for publication July 15, 2004.

Acknowledgments: We thank the clinical study team (B. M. Karakire, Marx Dongo, Sam Nsoya, Christopher Bongole, Regina Nakafero, Denise Njama, Anne Gasasira, Arthur Mpimbaza, Bridget K. Nzarubara, Pauline Byakika, and Sarah Kibirango); the community leaders from the Kawempe Division of Kampala; and the study participants and their parents/guardians for their support.

Financial support: This study was supported by the Fogarty International Center/National Institutes of Health (TW00007, TW01506, and AI43301) and the United Nations Development Program/World

Bank/World Health Organization Special Program for Research and Training in Tropical Diseases (TDR).

Authors' addresses: Grant Dorsey, Christian Dokomajilar, Sarah G. Staedke, and Philip J. Rosenthal. University of California at San Francisco, Parnassus Avenue, Box 0811 San Francisco, CA, 94143 Telephone: 415-206-4680 Fax: 415-648-8425, E-mail: grantd@itsa.ucsf.edu. Moses Kiggundu and Moses R. Kanya, Makerere University Medical School, Anatomy Building, Room C-443, Kampala, Uganda, Telephone: 256-41-251-387 Fax: 256-41-540-524.

REFERENCES

1. AFRO, Global AMDP Database. http://rbm.who.int/amdp/amdp_afro.htm.
2. Sibley CH, Hyde JE, Sims PF, Plowe CV, Kublin JG, Mberu EK, Cowman AF, Winstanley PA, Watkins WM, Nzila AM, 2001. Pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: what next? *Trends Parasitol* 17: 582–588.
3. White NJ, Nosten F, Looareesuwan S, Watkins WM, Marsh K, Snow RW, Kokwaro G, Ouma J, Hien TT, Molyneux ME, Taylor TE, Newbold CI, Ruebush TK, Danis M, Greenwood BM, Anderson RM, Olliaro P, 1999. Averting a malaria disaster. *Lancet* 353: 1965–1967.
4. Roper C, Pearce R, Bredekamp B, Gumede J, Drakeley C, Mosha F, Chandramohan D, Sharp B, 2003. Antifolate antimalarial resistance in southeast Africa: a population-based analysis. *Lancet* 361: 1174–1181.
5. World Health Organization, Position of WHO's Roll Back Malaria Department on Malaria Treatment Policy. <http://www.emro.who.int/rbm/>.
6. Wang P, Read M, Sims PF, Hyde JE, 1997. Sulfadoxine resistance in the human malaria parasite *Plasmodium falciparum* is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. *Mol Microbiol* 23: 979–986.
7. Peterson DS, Walliker D, Welles TE, 1988. Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. *Proc Natl Acad Sci USA* 85: 9114–9118.
8. Wang P, Sims PF, Hyde JE, 1997. A modified *in vitro* sulfadoxine susceptibility assay for *Plasmodium falciparum* suitable for investigating Fansidar resistance. *Parasitology* 115: 223–230.
9. Triglia T, Menting JG, Wilson C, Cowman AF, 1997. Mutations in dihydropteroate synthase are responsible for sulfone and sulfonamide resistance in *Plasmodium falciparum*. *Proc Natl Acad Sci USA* 94: 13944–13949.
10. Rallon NI, Osorio LE, Giraldo LE, 1999. Lack of an association between the ASN-108 mutation in the dihydrofolate reductase gene and *in vivo* resistance to sulfadoxine/pyrimethamine in *Plasmodium falciparum*. *Am J Trop Med Hyg* 61: 245–248.
11. Nzila AM, Nduati E, Mberu EK, Hopkins Sibley C, Monks SA, Winstanley PA, Watkins WM, 2000. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate pyrimethamine/sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan *Plasmodium falciparum*. *J Infect Dis* 181: 2023–2028.
12. Basco LK, Tahar R, Keundjian A, Ringwald P, 2000. Sequence variations in the genes encoding dihydropteroate synthase and dihydrofolate reductase and clinical response to sulfadoxine-pyrimethamine in patients with acute uncomplicated falciparum malaria. *J Infect Dis* 182: 624–628.
13. Alifrangis M, Enosse S, Khalil IF, Tarimo DS, Lemnge MM, Thompson R, Bygbjerg IC, Ronn AM, 2003. Prediction of *Plasmodium falciparum* resistance to sulfadoxine/pyrimethamine *in vivo* by mutations in the dihydrofolate reductase and dihydropteroate synthetase genes: a comparative study between sites of differing endemicity. *Am J Trop Med Hyg* 69: 601–606.
14. Aubouy A, Jafari S, Huat V, Migot-Nabias F, Mayombo J, Durand R, Bakary M, Le Bras J, Deloron P, 2003. DHFR and DHPS genotypes of *Plasmodium falciparum* isolates from Gabon correlate with *in vitro* activity of pyrimethamine and cycloguanil, but not with sulfadoxine-pyrimethamine treatment efficacy. *J Antimicrob Chemother* 52: 43–49.
15. Kyabayinze D, Cattamanchi A, Kanya MR, Rosenthal PJ, Dorsey G, 2003. Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. *Am J Trop Med Hyg* 69: 247–252.
16. Kublin JG, Dzinjalama FK, Kamwendo DD, Malkin EM, Cortese JF, Martino LM, Mukadam RA, Rogerson SJ, Lescano AG, Molyneux ME, Winstanley PA, Chimpeni P, Taylor TE, Plowe CV, 2002. Molecular markers for failure of sulfadoxine-pyrimethamine and chlorproguanil-dapsone treatment of *Plasmodium falciparum* malaria. *J Infect Dis* 185: 380–388.
17. Kanya MR, Dorsey G, Gasasira A, Ndeezi G, Babirye JN, Staedke SG, Rosenthal PJ, 2001. The comparative efficacy of chloroquine and sulfadoxine-pyrimethamine for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. *Trans R Soc Trop Med Hyg* 95: 50–55.
18. Dorsey G, Njama D, Kanya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ, 2002. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomized trial. *Lancet* 360: 2031–2038.
19. Warrell DA, Molyneux ME, Beales PF, 1990. Severe and complicated malaria. World Health Organization, Division of Control of Tropical Diseases. *Trans R Soc Trop Med Hyg* 84: 1–65.
20. World Health Organization, 1996. *Assessment of Therapeutic Efficacy of Antimalarial Drugs for Uncomplicated Falciparum Malaria in Areas with Intense Transmission*. Geneva: World Health Organization.
21. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, 2003. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. *Am J Trop Med Hyg* 68: 133–139.
22. Plowe CV, Djimde A, Bouare M, Doumbo O, Welles TE, 1995. Pyrimethamine and proguanil resistance-conferring mutations in *Plasmodium falciparum* dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. *Am J Trop Med Hyg* 52: 565–568.
23. Duraisingh MT, Curtis J, Warhurst DC, 1998. *Plasmodium falciparum*: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. *Exp Parasitol* 89: 1–8.
24. Staedke SG, Sendagire H, Lamola S, Kanya MR, Dorsey G, Rosenthal PJ, 2004. Relationship between age, molecular markers, and response to sulfadoxine-pyrimethamine treatment in Kampala, Uganda. *Trop Med Int Health* 9: 624–629.
25. Plowe CV, 2001. *Folate Antagonists and Mechanisms of Resistance*. Totowa, NJ: Humana Press.
26. Khalil I, Ronn AM, Alifrangis M, Gabar HA, Satti GM, Bygbjerg IC, 2003. Dihydrofolate reductase and dihydropteroate synthase genotypes associated with *in vitro* resistance of *Plasmodium falciparum* to pyrimethamine, trimethoprim, sulfadoxine, and sulfamethoxazole. *Am J Trop Med Hyg* 68: 586–589.
27. Nzila AM, Mberu EK, Sulo J, Dayo H, Winstanley PA, Sibley CH, Watkins WM, 2000. Towards an understanding of the mechanism of pyrimethamine-sulfadoxine resistance in *Plasmodium falciparum*: genotyping of dihydrofolate reductase and dihydropteroate synthase of Kenyan parasites. *Antimicrob Agents Chemother* 44: 991–996.
28. Hastings IM, Watkins WM, White NJ, 2002. The evolution of drug-resistant malaria: the role of drug elimination half-life. *Philos Trans R Soc Lond B Biol Sci* 357: 505–519.
29. Kanya MR, Bakayita NN, Talisuna AO, Were WM, Staedke SG, 2002. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. *Trop Med Int Health* 7: 1031–1041.
30. Dorsey G, Kanya MR, Ndeezi G, Babirye JN, Phares CR, Olson JE, Katabira ET, Rosenthal PJ, 2000. Predictors of chloroquine treatment failure in children and adults with falciparum malaria in Kampala, Uganda. *Am J Trop Med Hyg* 62: 686–692.
31. Dorsey G, Kanya MR, Singh A, Rosenthal PJ, 2001. Polymorphisms in the *Plasmodium falciparum* pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. *J Infect Dis* 183: 1417–1420.